SEC Form 4 · accession 0001209191-18-024991
Oncotelic Therapeutics, Inc. · OTLC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Donald Rogers Reynolds
Director
Period of report
Apr 12, 2018
Accepted (ET)
Apr 16, 2018 · 4:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000908259
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 12, 2018 | P$0 | 250,000 | — | A | 280,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock A Warrants (Right to Buy)F1 | $0.40 | Apr 12, 2018 | P | 125,000 | A | Apr 12, 2018 | Apr 12, 2020 | Common Stock | 125,000 | 125,000 | D |
| Common Stock B Warrants (Right to Buy)F1,F2,F3 | $0.40 | Apr 12, 2018 | P | 125,000 | A | — | — | Common Stock | 125,000 | 125,000 | D |
Explanation of responses
- F1The reported securities are included within one Unit purchased by the reporting person for $50,000 per Unit pursuant to a Subscription Agreement between the reporting person and Mateon Therapeutics, Inc. (the "Company"), dated April 12, 2018 (the "Subscription Agreement"). Each Unit consists of (i) 250,000 shares of Common Stock of the Company, par value $0.01 per share (the "Common Stock"), (ii) an "A" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share and (iii) a "B" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share.
- F2The Common Stock B Warrants shall become exercisable immediately following the Company's stockholders' approval of an increase in the number of the Company's authorized shares of Common Stock sufficient to cover the number of shares issuable upon the exercise of all of the Common Stock B Warrants issued pursuant to the Subscription Agreement (the "Stock Authorization"). The Company is obligated to effect the Stock Authorization no later than June 30, 2018 (the "Authorization Date").
- F3The Common Stock B Warrants shall expire on the date that is two years after the Stock Authorization is effected (the "Expiration Date"). In the event that the Company fails to effect the Stock Authorization by the Authorization Date, the Expiration Date will be extended for two additional years.